Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 16/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 16/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 12/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3068329 | 0.91 | GRIN2A (0.39) | GRIN1GRIN2AGRIA2GRM1 | |
| SCHEMBL3055945 | 0.88 | MEN1 (0.41) | GRIN1GRIN2AGRIA2GRM1NPC1 | |
| SCHEMBL3063760 | 0.87 | GRM1 (0.37) | GRM1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL3063987 | 0.87 | GRIN1 (0.43) | GRIN1GRIN2AGRIA2GRM1 | |
| SCHEMBL3059140 | 0.87 | MEN1 (0.45) | GRM1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL3064059 | 0.85 | GRM1 (0.34) | GRIN1GRIN2AGRIA2GRM1NPC1 | |
| SCHEMBL3068075 | 0.84 | MAPT (0.35) | GRM1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL8173447 | 0.84 | NPC1 (0.42) | GRM1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL3058858 | 0.84 | MEN1 (0.44) | GRM1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL3071290 | 0.83 | SMN1; SMN2 (0.38) | GRIN1GRIN2AGRIA2NPC1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | claimed |
| EP-2099754-A1 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-09-16 | — | — | EP | claimed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | claimed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | CACNA1E, CACNA1A, CACNA1S | GRIN1 165/4885GRIN2A 161/4885GRIA2 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.